All posts by medical

Gene editing stirs debate on ‘designer’ babies – The Straits Times

WASHINGTON CRISPR is a revolutionary gene-editing technique that allows scientists to insert, remove and correct DNA within a cell with pinpoint precision.

But gene editing is controversial because it involves altering the human genetic code. It also evokes a future where humans can order "designer" babies with specific features - blonde hair, athleticism, perhaps even intelligence. That, though, is some way off as scientists say we do not yet know how to genetically enhance such traits.

Yet, there is also the prospect of avoiding heritable, genetic diseases that can handicap or kill, meaning a chance to improve a human life.

For Professor Peter Braude, a reproductive health expert from King's College London, the study showed that "germ line genome editing has moved from future fantasy to the world of possibility". The debate about using it in practice "needs to run to catch up".

Professor Darren Griffin of the University of Kent, in Britain, said: "Perhaps the biggest question, and probably the one that will be debated the most, is whether we should be physically altering the genes of an IVF (lab- created) embryo at all.

"Equally, the debate on how morally acceptable it is not to act when we have the technology to prevent these life-threatening diseases must also come into play."

Currently, the only way to avoid heritable disease in assisted reproduction is to fertilise eggs in the lab, analyse the DNA of the resulting embryos, and eliminate those containing errors.

Much more research is needed before the method can be tested in clinical trials, now impermissible under US federal law. But if the technique is found to work safely with this and other mutations, it might help couples who could not otherwise have healthy children. Potentially, it could apply to any of more than 10,000 conditions caused by specific inherited mutations.

Researchers and experts said those might include breast and ovarian cancer, as well as diseases like Huntington's, Tay-Sachs, beta thalassemia, and even sickle cell anaemia, cystic fibrosis or some cases of early-onset Alzheimer's.

"You could certainly help families who have been blighted by a horrible genetic disease," said Dr Robin Lovell-Badge, a professor of genetics and embryology at the Francis Crick Institute in London, who was not involved in the study.

Concerns, though, remain.

A group of 11 organisations, including the American Society of Human Genetics and Britain's Wellcome Trust, on Wednesday issued a statement recommending against genome editing that culminates in human implantation and pregnancy, while supporting publicly funded research into its potential clinical applications.

AGENCE FRANCE-PRESSE, NYTIMES, REUTERS

Read the original:
Gene editing stirs debate on 'designer' babies - The Straits Times

Testing the Strength and Durability of Spider Silk – AZoM

A global education facility, The University of Nottingham has campuses in Malaysia, China and the United Kingdom. A depth of expertise in the fields of Zoology, Anatomy, Physiology, Pharmacology, Microbiology, Genetics, Biochemistry and Molecular and Cell Biology can be found in the School of Life Sciences within the Faculty of Medicine and Health Sciences.

This wide range of expertise places the University of Nottingham at the forefront of Medical Science and Biological research. One particular project is involved in molecular genetic studies of spider silk and extensive knowledge of this topic has relevance in many fields from pure education to future engineering applications.

Working with colleagues across the University, including the Nanoscience and Nanotechnology Centre, the Spider Lab team had to test the physical properties of specific types of this natural protein.

However, the fiber test specimens are usually only a few tens of microns in width, even though the raw materials are generated by some of the largest members of the infra order for instance the Mexican red knee tarantula (Brachypelma smithi). Hence, in addition to the highest levels of accuracy, the solution demanded delicate yet secure gripping for valid research data.

Mexican Red Knee Tarantula with Silk Sample and Holder.

Lightweight Grips, Spring-loaded and Rubber-faced.

A computer-controlled test stand was delivered by Mecmesin, with an appropriately rated load cell and fixtures, selected to optimize resolution at the maximum expected tensile forces.

The test procedure is controlled by the emperor software

and the programming environment enables specific calculations to be carried out to systematically characterize the performance of the silk sample. Measurement of extension rate, average load over specific extension ranges, work performed, elongation and load at break are recorded.

Thus, this broad analysis provides a better understanding about the variability amongst silks (and between strands of the same silk type). The library files make sure that the same extension test is repeated several times for the same fiber, or bundles of fibers which replicates the natural ecological use of the material.

By bonding the fiber or fibers to a card frame, which is cut in two before the test, the test sample is secured. The precision specification is completed by lightweight grips - spring-loaded clamping for the upper and rubber-faced jaws in the lower.

The Mecmesin machine is a great piece of kit it has allowed us to move forward with our research in a very productive way, and we are grateful for the excellent technical support that has come with it.

Dr. Sara Goodacre, Assistant Professor, Faculty of Medicine & Health Sciences, The University of Nottingham

This information has been sourced, reviewed and adapted from materials provided by Mecmesin Limited.

For more information on this source, please visit Mecmesin Limited.

See the rest here:
Testing the Strength and Durability of Spider Silk - AZoM

Joyce Harper – The Conversation UK

Profile Articles Activity

Joyce Harper is Professor of Human Genetics and Embryology at University College London in the Institute for Womens Health where she is head of the Reproductive Health Department, Principal Investigator of the Embryology, IVF and Reproductive Genetics Group, Director of Education and Director of two MSc programmes - Prenatal Genetics and Fetal Medicine and Reproductive Science and Womens Health. She has been working in the fields of IVF and reproductive genetics since 1987 and written over 170 scientific papers and published two textbooks. Her research includes preimplantation genetic diagnosis, factors affecting preimplantation development, comparison of in vivo and in vitro development, differences in culture media, embryo selection methods, sperm DNA damage and social and ethical issues surrounding IVF and reproductive genetics including gamete donation, surrogacy, social egg freezing, religious views to ART and fertility education and awareness.

Joyce is passionate about public engagement to discuss all aspects of womens health, including wellbeing. She has established a public engagement group with daily posts http://www.globalwomenconnected.com. Joyce is writing a book covering womens health from birth to death. She is deputy chair of the UK Fertility Education Initiative, trying to improve fertility awareness in the UK and a member of the Fertility Arts Education Project Steering Group.

Joyce has had many senior roles in the European Society of Human Reproduction and Embryology (ESHRE), including establishing the ESHRE PGD Consortium. She is chair of the HFEA Horizon Scanning Group and an advisor to the HFEA Science and Clinical Advances Advisory Committee. She is on the Board of the British Fertility Society. She is a member of the Nuffield Council for Bioethics working group on genome editing.

For further information see http://www.joyceharper.com.

1987

Kings College London, PhD

1984

Queen Elizabeth College, BSc

Read more:
Joyce Harper - The Conversation UK

Johns Hopkins center receives $300M from USAID to encourage healthy behaviors in developing countries – The Hub at Johns Hopkins

ByStephanie Desmon

The Johns Hopkins Center for Communication Programs has received a five-year award with a $300 million ceiling from the United States Agency for International Development to lead its social and behavior change programs around the world.

Breakthrough-ACTION will use evidence-based tools to encourage people in developing countries to adopt healthy behaviors, from using modern contraceptive methods to sleeping under bed nets to being tested for HIV.

Susan Krenn

Executive director, CCP

Much of the work will harness the power of communicationfrom mass media campaigns to TV and radio dramas to simple posters in a health clinicto inspire long-lasting change. It will be led by CCP, which is based at the Johns Hopkins Bloomberg School of Public Health.

"American security is advanced by supporting social and behavioral interventions, which improve health and promote social stability for people living in low- and middle-income countries," says Michael J. Klag, dean of the Bloomberg School. "Such evidence-based, innovative, and creative interventions should be part and parcel of every international health development program. This new award emphasizes the value of investing in social and behavior change programs."

The program builds on a prior five-year, $144 million, 31-country project called the Health Communications Capacity Collaborative, or HC3, and is expected to be double the size.

CCP will partner with:

Breakthrough-ACTION will also be supported in the field by ActionSprout, the International Center for Research on Women, and Human Network International.

"Harmful social norms and behavioral challenges stand in the way of better health, education, and livelihood for far too many people around the globe," says Susan Krenn, CCP's executive director. "With this investment, we have an incredible opportunity to test and scale new approaches, increase efficiency, and to serve more people. We can't wait to get started."

The Breakthrough-ACTION agreement was effective July 21, with work expected to begin immediately. While the exact geographic scope of the project has not yet been finalized, CCP expects to work in dozens of countries, primarily in Africa and Asia. CCP will build on previous successes in some countries and establish new partnerships in others.

While communication is at the heart of Breakthrough-ACTION, the project will also use other behavioral science approaches such as human-centered design and behavioral economics to create social and behavior change at the global, regional, and country level. CCP will use the expertise it gained during the recent West African Ebola outbreak to do similar emergency response work if needed.

Krenn says the award reflects new understandings about what works in international development.

"People are now appreciating that you need to do more than just build a health clinic and expect people to come," she says. "You have to motivate them, give them a reason to go. People need the information to make decisions for themselves and their families, especially when you're asking them to do something that isn't common practice such as sleeping under bed nets or accessing modern contraception. This kind of work provides the missing link, helping to motivate people to make better health decisions."

USAID administers the U.S. foreign assistance program providing economic and humanitarian assistance in 100 countries worldwide.

David Holtgrave, professor and chair of the Bloomberg School's Department of Health, Behavior and Society, says the work of CCP shows the vital role behavior change can play in saving lives.

"Too often, when people think of development, they think only of food aid or drugs for health clinics and the like," he says. "What our work proves is that communication is an essential part of any comprehensive, effective development program."

See more here:
Johns Hopkins center receives $300M from USAID to encourage healthy behaviors in developing countries - The Hub at Johns Hopkins

‘Grey’s Anatomy’ Star Announces Return To Season 14 Set – People’s Choice

Johnni Macke 3:00 pm on July 31, 2017

(ABC/Richard Cartwright)

Greys Anatomyseason 14 is currently underway, and one key star is ready to start filming!

On Monday (July 31), Sarah Drew, who plays Dr. April Kepner, announced that shes officially back for season 14 with a shout-out to her character and a boost of morning coffee.

Took me a minute to realize the coffee was for me I guess the timing is right, since I step back into Aprils shoes today!! Were baaack!!! #GreysAnatomy #season14, Drew captioned her morning fuel.

The last time we saw April, she was being surprisingly supportive of her ex-husband Dr. Jackson Averys (Jesse Williams) new flame (or the girl he is currently smitten with), Dr. Maggie Pierce (Kelly McCreary). After April tells Maggie that Jackson has feelings for her she points out that Maggie clearly likes him too.

Because I have a feeling you like him, so why dont you just tell him? April says, causing Maggie to really think about what could happen between her and Jackson, and leaving fans a little baffled by a possible love triangle, or new romance that may, or may not, include April next season.

The good news is that no matter what April is up to come season 14, the actress is back with coffee in hand to make us tune in week after to week to see what happens next with her character. Now if only we knew what CACML stood for on her coffee order, then we too could run on doctor fuel!

Greys Anatomy returns for its 14th season with a two-hour premiere on September 28, 2017 at 8 p.m. on ABC.For the latest pop culture news and voting, make sure to sign up for the Peoples Choice newsletter!

The rest is here:
'Grey's Anatomy' Star Announces Return To Season 14 Set - People's Choice

A life-changing genetics breakthrough deserves celebration and demands caution – Washington Post

THE NEWS that researchers have carried out the first known attempt to create genetically modified human embryos is another signpost in an astounding revolution unfolding before our eyes. This is not the first breakthrough nor will it be the last, but it should serve as a reminder an unmistakable one that this realm of scientific inquiry, manipulating the tiny building blocks of life, demands caution as well as enthusiasm and encouragement.

The latest effort, led by Shoukhrat Mitalipov of Oregon Health & Science University, with researchers from South Korea, China, the Salk Institute for Biological Studies in California and others, involved editing the DNA of single-cell embryos with CRISPR-Cas9, a tool for genome engineering that is much simpler, faster and cheaper than earlier methods, and which has sparked an explosion of interest in possible applications. According to a report published Wednesday in the journal Nature, the researchers were able to demonstrate that it is possible to safely and efficiently correct defective genes that cause inherited diseases.

The embryos they modified were not allowed to develop for more than a few days and were not implanted in a womb. In earlier research in China, the modified DNA was taken up by only some cells, not all, and suffered other setbacks, raising questions about its effectiveness. The latest research team reports it achieved efficiency, accuracy and safety with the approach.

If so, the research may be yet another step toward what is called germline engineering, or changing the genetic material in reproductive cells, so that any offspring would pass the changes on to future generations. The potential impact is huge; thousands of inherited diseases are caused by mutations in single genes, so editing the germline cells of individuals who carry these mutations could allow them to have children without the risk of passing on the conditions.

But the dangers and concerns are also significant. The technique could be used to enhance human traits beyond just eradicating disease, such as creating designer babies, or for other malevolent purposes. Genome editing was singled out for concern in a 2016 report to Congress from the U.S. intelligence community about potential wordwide threats: Given the broad distribution, low cost, and accelerated pace of development of this dual-use technology, its deliberate or unintentional misuse might lead to far-reaching economic and national security implications.

In a report this year, a panel of the National Academy of Sciences addressed the potential and the risks of germline engineering, concluding that basic research should proceed, closely watched. But the panel also said, Do not proceed at this time with human genome editing for purposes other than treatment or prevention of disease and disability. This seems to us to strike a reasonable balance, but one that will require vigilance transparency, oversight and public awareness to ensure the fruits of this remarkable revolution are not somehow abused or misused.

Read the original here:
A life-changing genetics breakthrough deserves celebration and demands caution - Washington Post

Why Neuroscience Is the Key To Innovation in AI – Singularity Hub – Singularity Hub

The future of AI lies in neuroscience.

So says Google DeepMinds founder Demis Hassabis in a review paper published last week in the prestigious journal Neuron.

Hassabis is no stranger to both fields. Armed with a PhD in neuroscience, the computer maverick launched London-based DeepMind to recreate intelligence in silicon. In 2014, Google snagged up the company for over $500 million.

Its money well spent. Last year, DeepMinds AlphaGo wiped the floor with its human competitors in a series of Go challenges around the globe. Working with OpenAI, the non-profit AI research institution backed by Elon Musk, the company is steadily working towards machines with higher reasoning capabilities than ever before.

The companys secret sauce? Neuroscience.

Baked into every DeepMind AI are concepts and ideas first discovered in our own brains. Deep learning and reinforcement learningtwo pillars of contemporary AIboth loosely translate biological neuronal communication into formal mathematics.

The results, as exemplified by AlphaGo, are dramatic. But Hassabis argues that its not enough.

As powerful as todays AIs are, each one is limited in the scope of what it can do. The goal is to build general AI with the ability to think, reason and learn flexibly and rapidly; AIs that can intuit about the real world and imagine better ones.

To get there, says Hassabis, we need to closer scrutinize the inner workings of the human mindthe only proof that such an intelligent system is even possible.

Identifying a common language between the two fields will create a virtuous circle whereby research is accelerated through shared theoretical insights and common empirical advances, Hassabis and colleagues write.

The bar is high for AI researchers striving to bust through the limits of contemporary AI.

Depending on their specific tasks, machine learning algorithms are set up with specific mathematical structures. Through millions of examples, artificial neural networks learn to fine-tune the strength of their connections until they achieve the perfect state that lets them complete the task with high accuracymay it be identifying faces or translating languages.

Because each algorithm is highly tailored to the task at hand, relearning a new task often erases the established connections. This leads to catastrophic forgetting, and while the AI learns the new task, it completely overwrites the previous one.

The dilemma of continuous learning is just one challenge. Others are even less defined but arguably more crucial for building the flexible, inventive minds we cherish.

Embodied cognition is a big one. As Hassabis explains, its the ability to build knowledge from interacting with the world through sensory and motor experiences, and creating abstract thought from there.

Its the sort of good old-fashioned common sense that we humans have, an intuition about the world thats hard to describe but extremely useful for the daily problems we face.

Even harder to program are traits like imagination. Thats where AIs limited to one specific task really fail, says Hassabis. Imagination and innovation relies on models weve already built about our world, and extrapolating new scenarios from them. Theyre hugely powerful planning toolsbut research into these capabilities for AI is still in its infancy.

Its actually not widely appreciated among AI researchers that many of todays pivotal machine learning algorithms come from research into animal learning, says Hassabis.

An example: recent findings in neuroscience show that the hippocampusa seahorse-shaped structure that acts as a hub for encoding memoryreplays those experiences in fast-forward during rest and sleep.

This offline replay allows the brain to learn anew from successes or failures that occurred in the past, says Hassabis.

AI researchers snagged the idea up, and implemented a rudimentary version into an algorithm that combined deep learning and reinforcement learning. The result is powerful neural networks that learn based on experience. They compare current situations with previous events stored in memory, and take actions that previously led to reward.

These agents show striking gains in performance over traditional deep learning algorithms. Theyre also great at learning on the fly: rather than needing millions of examples, they just need a handful.

Similarly, neuroscience has been a fruitful source of inspiration for other advancements in AI, including algorithms equipped with a mental sketchpad that allows them to plan convoluted problems more efficiently.

But the best is yet to come.

The advent of brain imaging tools and genetic bioengineering are offering an unprecedented look at how biological neural networks organize and combine to tackle problems.

As neuroscientists work to solve the neural codethe basic computations that support brain functionit offers an expanding toolbox for AI researchers to tinker with.

One area where AIs can benefit from the brain is our knowledge of core concepts that relate to the physical worldspaces, numbers, objects, and so on. Like mental Legos, the concepts form the basic building blocks from which we can construct mental models that guide inferences and predictions about the world.

Weve already begun exploring ideas to address the challenge, says Hassabis. Studies with humans show that we decompose sensory information down into individual objects and relations. When implanted in code, its already led to human-level performance on challenging reasoning tasks.

Then theres transfer learning, the ability that takes AIs from one-trick ponies to flexible thinkers capable of tackling any problem. One method, called progressive networks, captures some of the basic principles in transfer learning and was successfully used to train a real robot arm based on simulations.

Intriguingly, these networks resemble a computational model of how the brain learns sequential tasks, says Hassabis.

The problem is neuroscience hasnt figured out how humans and animals achieve high-level knowledge transfer. Its possible that the brain extracts abstract knowledge structures and how they relate to one another, but so far theres no direct evidence that supports this kind of coding.

Without doubt AIs have a lot to learn from the human brain. But the benefits are reciprocal. Modern neuroscience, for all its powerful imaging tools and optogenetics, has only just begun unraveling how neural networks support higher intelligence.

Neuroscientists often have only quite vague notions of the mechanisms that underlie the concepts they study, says Hassabis. Because AI research relies on stringent mathematics, the field could offer a way to clarify those vague concepts into testable hypotheses.

Of course, its unlikely that AI and the brain will always work the same way. The two fields tackle intelligence from dramatically different angles: neuroscience asks how the brain works and the underlying biological principles; AI is more utilitarian and free from the constraints of evolution.

But we can think of AI as applied (rather than theoretical) computational neuroscience, says Hassabis, and theres a lot to look forward to.

Distilling intelligence into algorithms and comparing it to the human brain may yield insights into some of the deepest and most enduring mysteries of the mind, he writes.

Think creativity, dreams, imagination, andperhaps one dayeven consciousness.

Stock Media provided by agsandrew / Pond5

Read the original:
Why Neuroscience Is the Key To Innovation in AI - Singularity Hub - Singularity Hub

GSK to shutter central neuroscience R&D hub in China – FierceBiotech

After reports surfaced in the Chinese press this week, GlaxoSmithKline has confirmed to FierceBiotech that it will be shutting down operations at its Shanghai R&D base as it looks west.

The U.K.-based drugmaker told FierceBiotech,Following a portfolio review and prioritization, GSK has decided to close its Neuroscience R&D Centre in Shanghai and move key programs to its global R&D hub in Upper Providence in the U.S., where they will benefit from co-location with other pipeline R&D programs."

The China R&D development organization will continue to be based in Shanghai and is set to expand over the next two years to accelerate the development of new medicines. We remain committed to China and will focus our R&D efforts in China on the needs of China, at both our Shanghai site and our Institute for Infectious Diseases and Public Health in Beijing. It did not say how many staffers would be affected.

This comes less than a year after the company looked to strengthen its China R&D commitment. Li Min, GSK's global head of neurosciences and general manager of R&D China, said last year, as quoted by news site China Daily: In the field of neurological diseases, we are very much committed to neurodegeneration and neuroexcitation. In medicine, you need to stay focused. You have to commit to one direction and make it happen.

Two yearsago, it launched the Neuro2020 project, encouraging partnerships with local universities, something Li said was part of our five-year plan to establish both our research as well as connectivity to the rest of our ecosystem, especially in China.

GSK has, of course, had a rather difficult past in the region. China is a major world economy with a growing middle class and the potential for big pharmaceutical sales and R&D, but tough policies led by a central and uncompromising government have made western biopharma expansion into China problematic.

Back in 2013,GSK became embroiled in a sex, lies and videotape-type scandal that saw allegations of bribery from certain sales teams in the region, with a deeper twist when a sex tape of former head of GSK China, Mark Reilly, in his Shanghai apartment with his girlfriend, was alleged to have been made, and then sent to CEO Andrew Witty. Witty has since been replaced by Emma Walmsley, who announced last month a major shake-up of the companys R&D.

Walmsley said she was focusing GSKs attention on two therapeutic areas in which it already has a sizable presencerespiratory and HIV/infectious diseasesand two in which it aspires to growoncology and immuno-inflammation. GSK will spend 80% of its R&D budget on top prospects in these areas. Neuroscience was not on her list of core areas to focus on.

See the article here:
GSK to shutter central neuroscience R&D hub in China - FierceBiotech